Clinical trials
Phase 1/2 Lymphoma, Large B-Cell, Diffuse trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 4 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 14 |
| Recruiting | 12 |
| Not yet recruiting | 5 |
| Terminated | 3 |
| Completed | 3 |
| Active, not recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chinese PLA General Hospital | 3 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 3 |
| Sun Yat-sen University | 3 |
| BeiGene | 2 |
| Huiqiang Huang | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 2 |
| Antengene Corporation | 1 |
| BeOne Medicines | 1 |
| BioNova Pharmaceuticals (Shanghai) LTD. | 1 |
| Centaurus Biopharma Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Large B-Cell, Diffuse | 40 |
| Lymphoma, Follicular | 16 |
| Lymphoma, Mantle-Cell | 14 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 13 |
| Recurrence | 7 |
| Lymphoma, B-Cell | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Hematologic Neoplasms | 4 |
| Lymphoma | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.